Gut microbiota-derived butyrate ameliorates pediatric IgA vasculitis via GPR43 by inhibiting the NF-κB/NLRP3 inflammatory cascade and attenuating Tfh17-driven IgA production
Year: 2026
Type: preprint
Abstract: Immunoglobulin A vasculitis (IgAV) is the most common pediatric systemic small-vessel vasculitis, with renal involvement directly determining long-term prognosis; yet no etiology-targeted interventions are clinically available. Butyrate, a gut microbiota-derived metabolite that regulates mucosal immune homeostasis, has unclear mechanisms underlying its effects on IgAV-associated multiorgan damage. Here we show that butyrate-producing microbiota are specifically depleted in children with active IgAV. Among seven major short-chain fatty acids, only butyrate is significantly decreased and tends to be negatively correlated with disease activity and renal injury indices. Using an ovalbumin-induced IgAV rat model, we demonstrate that sodium butyrate and Clostridium butyricum both reduce IgA immune complex deposition and multi-organ inflammatory infiltration via GPR43, synergistically repairing the intestinal barrier, suppressing NF-κB/NLRP3 activation and IL-6/STAT3-dependent Tfh17 differentiation, and inhibiting aberrant IgA production. These findings reveal a gut dysbiosis–butyrate deficiency–IgAV pathogenesis cascade, supporting butyrate-based preparations as a promising etiology-targeted intervention for IgAV.
Source: Research Square
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7236291592
